Genmab Revises 2026 Adjusted Operating Profit Guidance To $1.07 Billion To$1.39 Billion
GMAB•First-half 2026 results and updated guidance
Aug. 6 (Reuters) - Genmab A/S (GMAB.CO):
- Genmab announces financial results for the first half of 2026
- Genmab - net sales of Darzalex by J&J $8.17 billion for first six months of 2026, up 21%
- Genmab - adjusted operating profit $656 million for first six months of 2026
- Genmab - revises 2026 revenue guidance to $4,325 million-$4,525 million
- Genmab - revises 2026 adjusted operating profit guidance to $1.07 billion - $1.39 billion
